Please assess the completion status of the following clinical trial:

Trial Title: Monoclonal Antibody Treatment for Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
* IINCLUSION CRITERIA:~Age at entry at least 18 years~Must give written informed consent prior to entry in the protocol~Must fulfill at least 4 of the following criteria for SLE as defined by the American College of Rheumatology:~* Malar rash. Fixed Erythema, flat or raised, over the malar eminences.~* Discoid rash. Erythematous raised patches with adherent keratotic scaling and follicular plugging; atrophic scarring may occur.~* Photosensitivity. Exposure to UV light causes rash.~* Oral Ulcers. Includes oral and nasopharyngeal, observed by physician.~* Arthritis. Nonerosive arthritis involving two or more peripheral joints, characterized by tenderness, swelling or effusion.~* Serositis. Pleuritis or pericarditis documented by ECG or rub or evidence of pericardial effusion.~* Renal disorder. Proteinuria greater than 0.5 g/d or greater than 3+, or cellular casts.~* Neurologic disorder. Seizures without other cause or psychosis without other cause.~* Hematologic disorder. Hemolytic anemia or leukopenia (less than 4000/microL) or lymphopenia (less than 1500/microL) or thrombocytopenia (less than 100,000/microL) in the absence of offending drugs.~* Immunologic disorder. Anti-dsDNA, anti-Sm, and/or anti-phospholipid.~* Antinuclear antibodies. An abnormal titer of ANAs by immunofluorescence or an equivalent assay at any point in time in the absence of drugs known to induce ANAs.~Moderately active lupus not requiring immediate immunosuppressive therapy other than oral prednisone less than or equal to 0.3 mg/kg/day (or its equivalent). Moderately active lupus is defined by either of these two (a and b) sets of criteria:~a. Chronic glomerulonephritis with inadequate response to at least 6 months of adequate immunosuppressive therapy (with pulse methylprednisolone, cyclophosphamide, azathioprine, cyclosporine, mycophenolate mofetil or high dose daily corticosteroids, MTX or IV Ig), and~i. less than 30% increase in creatinine compared to lowest level during treatment,~ii. proteinuria less than or equal to 1.5 times the baseline before treatment,~iii. less than or equal to 2+ cellular casts in the urinary sediment (on a scale of 0-4), and~iv. Extra-renal disease activity does not exceed 10 on the non-renal components of the SELENA-SLEDAI score.~b. Patients with moderately active extra-renal lupus defined as an extra-renal SELENA-SLEDAI score in the range of 3 to 10, inclusive. The SELENA-SLEDAI score should have been stable for at least two weeks prior to screening.~One or more of the following:~i) Serum dsDNA level greater than or equal to 30 IU~ii) IgG anticardiolipin antibody levels greater than or equal to 20 GPL~iii) CRP greater than 0.8 mg/dL~iv) ESR greater than 25 mm/hr for men; ESR greater than 42 mm/hr for women.~Stable doses of prednisone less than or equal to 0.3 mg/kg/day (or its equivalent) for at least 2 weeks before the first treatment.~EXCLUSION CRITERIA:~Pregnant or lactating women. Women of childbearing potential are required to have a negative pregnancy test at screening.~Women of childbearing potential and fertile men who are not practicing or who are unwilling to practice birth control during and for a period of three months after the completion of the study~Any therapy with human or murine antibodies or any experimental therapy within 3 months~Therapy with cyclophosphamide; pulse methylprednisolone or IV Ig within 4 weeks; or azathioprine, mycophenolate mofetil, cyclosporine or methotrexate within 2 weeks of first study treatment~Initiation or a change in the dose of an ACE-inhibitor within 2 weeks of first study treatment~Allergy to murine or human antibodies~History of anaphylaxis~Serum creatinine greater than 3.0 mg/dL~Active severe CNS lupus (encephalopathy, cerebrovascular accident, transverse myelitis, severe depression, psychosis)~Previous history of ischemic heart disease or evidence of ischemic heart disease on ECG~Congestive heart failure or cardiomyopathy~History of thrombosis or recurrent 2nd trimester abortions (3 or more) and elevated levels of anti-cardiolipin antibodies or lupus anticoagulant unless the patient is on anticoagulation~History of malignancy with the exception of basal cell or squamous cell carcinoma of the skin or in situ carcinoma of the cervix within the last 3 years~Active infection that requires the use of intravenous antibiotics and does not resolve within 1 week of Day 1~Any active viral infection that does not resolve within 10 days prior to Day 1~History of reactivation on EB viral infection or greater than 1,000 EBV genome equivalent/10(6) cells in PBMC preparations~Active hepatitis B, hepatitis C or HIV infection~WBC less than 3500/microL or ANC less than 3000/microL or Hgb less than 8.0 g/dL or platelets less than 50,000/microL or absolute lymphocyte count less than or equal to 500/microL.~ALT and/or AST greater than 2 times the upper limit of normal (ULN) or alkaline phosphatase greater than 1.5 times the ULN~Significant concurrent medical condition that, in the opinion of the principal investigator, could affect the patient's ability to tolerate or complete the study~Live vaccines within 4 weeks of first infusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete